New startup ideas · Health and bio · Healthcare and bio
startup idea
Benchline
A regulated marketplace that puts any lab test on any clinic's benchtop.
Benchline builds one cleared benchtop analyzer and runs the two-sided marketplace on top of it: assay developers publish cartridge tests through Benchline's shared regulatory rails, and independent clinics, pharmacies and veterinary practices buy tests per run.
- Marketplace
- Small business
- $10-100B market
- Collapses a cost 10x
- Global from day one
3/5
venture judge
21
similar startups, last 2 years (75 all-time)
79%
of 3 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
62
Idea Score, 0-100 · raw 38.0 x 1.64
Crowded
competition: more crowded than 88% of ideas · headwind x0.56
+4.6
government priorities, secondary (118 matching grants)
Trend
48
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)23
- Rounds announced 2025+ in the sector68
- Sector direction (live batch)100
- 2026 trend analyst0
Demand
60
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain50
100x potential
74
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge50
- Market size axis67
- Moat axis100
- Neighbours still alive76
- Technologist judge100
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were regulated, marketplace, puts, lab, test, clinic, benchtop, builds.
The idea in full
- What
- Benchline builds one cleared benchtop analyzer and runs the two-sided marketplace on top of it: assay developers publish cartridge tests through Benchline's shared regulatory rails, and independent clinics, pharmacies and veterinary practices buy tests per run. A panel that costs a small practice 100-plus dollars and two days as a send-out to a central lab runs on the bench in minutes at roughly a tenth of the price, with Benchline taking a cut of every cartridge.
- Why now
- Point-of-care hardware is getting funded again in a cluster that added 199 new companies in 2024 alone - YC X26's Lumius is building 3D ultrasound anyone can use and 500 Global's Carevision pitches 60-second cardiometabolic screening - but each of these devices ships as a closed, single-vendor system with one test menu.
- Wedge: first customer and entry point
- Start with two or three high-volume CLIA-waived-class assays for independent primary care and veterinary clinics, sold through existing diagnostics distributors who already own those relationships, before opening the developer side of the marketplace.
- Path to 100x
- In-vitro diagnostics is a market in the tens of billions, held today by central labs whose send-out pricing Benchline undercuts 10x. If the installed base reaches critical mass, every new assay developer must launch on Benchline to reach clinics and every new clinic buys the device to access the assay catalog - app-store take-rate economics with two-sided lock-in that makes decentralized testing winner-take-most.
- Ceiling
- Incumbent central labs cut send-out prices before the installed base reaches critical mass, freezing Benchline at a niche of remote and veterinary sites.
- Closest real companies, as the generator saw them
- Lumius and Carevision Inc. are single-device, single-menu point-of-care companies; Rebio Health builds one medical device for one indication. Benchline is the market between assay developers and clinics, not another closed instrument.
- Main risk
- The first assay clearances take so long and cost so much that the company burns out before the developer side of the marketplace exists.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
3/5
App-store economics on a cleared analyzer is a genuine power-law shape, but assay clearances gate the developer side for years.
Bootstrapper
1/5
Assay clearances plus a cleared benchtop analyzer are the exact hardware-and-regulatory prepay this lens refuses.
Operator
3/5
A 100-dollar two-day send-out collapsing to minutes at a tenth the price is money clinics already spend, but assay clearance delays the payoff for years.
Technologist
5/5
One cleared analyzer plus open cartridge rails for third-party assay developers is hardware, regulatory and platform work that compounds with every assay added.
Risk
2/5
Cleared analyzer plus per-assay clearances make regulatory timelines the single point of failure, with distributor relationships owning the clinic channel Benchline needs.
trends
1/5
Multi-year assay clearances mean any 2026 window closes before launch, and 'hardware getting funded again' was equally said in 2021.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (regulated, marketplace, puts, lab, test, clinic, benchtop, builds): 75 all-time, 21 from the last two years. Same matching as Idea Check.
A primary care clinic where AI earns clinical autonomy
Empowering next-gen precision oncology with scalable, in-house AI biomarkers from routine pathology slides.
We build networks of AIs to simulate high-value audiences
At-cost lab testing marketplace that profits when you test less
API for at-home clinical sample collection.
Living therapies for pets first, and their people next
AIoT monitoring, workflow, and evidence systems for regulated labs.
Laboratory Information Management System (LIMS) serving…
Precision oncology company focused on transforming patient care and conquering cancer with data
Levisonics is developing a drop-of-blood, point-of-care coagulation analyzer that delivers in a single test the comprehensive clotting insights that today require multiple separate lab and point-of-care tests.
The intelligent development platform for robotics
Reliable infrastructure to build, deploy and manage real-world robots.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1127
startup-relevant grants in Healthcare and bio
$590M
awarded in the sector, tracked
130
opportunities open now in the sector
- FlyBand-Peds: Evaluating Biomechanics of Integrated Exoskeleton Footwear for Pediatric Charcot-Marie-Tooth Diseaseawardhigh relevance
NIH / NICHD · SBIR phase I · $306K · posted 2026-08-01
- I-Corps: Translation potential of a cell culture technology that synchronizes cellular circadian rhythms through precise temperature oscillationsawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-07-24
NIH / NINDS · SBIR phase II · $1M · posted 2026-07-14
NIH / NIA · STTR phase I · $307K · posted 2025-09-20
- Patient-Centered Self-Cannulation Training Simulator to Promote Self-Care and Home Hemodialysis among African American Patients with Kidney Failureawardhigh relevance
NIH / NIMHD · SBIR phase I · $350K · posted 2025-09-17
NIH / NIDDK · SBIR phase I · $287K · posted 2025-09-11
NIH / NIAID · SBIR phase I · $307K · posted 2025-09-05
NIH / NIDCD · STTR phase I · $293K · posted 2025-09-01
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Small business
- Business model
- Marketplace
- Path to 100x
- Collapses a cost 10x
- Market size
- $10-100B market
- Capital intensity
- Capital-heavy (hardware, bio, infra)
- Speed to revenue
- R&D first, revenue after 3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Partners and channels
- Moat
- Network effects
- Geography
- Global from day one
- Regulation
- Heavily regulated
- Vibe
- Boring business
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-26 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.